Rosas Lab

Dr. Rosas’ research group has a long-standing clinical research interest in the natural history of early pulmonary fibrosis in susceptible cohorts, has extensively phenotyped patients affected with sporadic idiopathic pulmonary fibrosis, kindred’s affected with familial pulmonary fibrosis, and patients with rheumatoid arthritis affected with secondary pulmonary fibrosis.

More recently the group has focused on characterizing interstitial lung abnormalities in smokers and found that interstitial lung abnormalities are associated with significant reduction in lung volumes and inversely correlated with development of emphysema. These findings suggest that distinct pathobiological processes are involved in the development of pulmonary fibrosis and emphysema.

Dr. Rosas is also interested in the development of biomarkers and therapies for human pulmonary fibrosis and presently serves as the Brigham and Women's Hospital principal investigator for IPFnet. He is a co-investigator in an NIH sponsored multicenter study to test the therapeutic role of low-dose inhaled carbon monoxide in IPF.